Literature DB >> 15536458

In vivo assessment of botanical supplementation on human cytochrome P450 phenotypes: Citrus aurantium, Echinacea purpurea, milk thistle, and saw palmetto.

Bill J Gurley1, Stephanie F Gardner, Martha A Hubbard, D Keith Williams, W Brooks Gentry, Julie Carrier, Ikhlas A Khan, David J Edwards, Amit Shah.   

Abstract

OBJECTIVES: Phytochemical-mediated modulation of cytochrome P450 (CYP) activity may underlie many herb-drug interactions. Single-time point phenotypic metabolic ratios were used to determine whether long-term supplementation of Citrus aurantium , Echinacea purpurea , milk thistle (Silybum marianum), or saw palmetto (Serenoa repens) extracts affected CYP1A2, CYP2D6, CYP2E1, or CYP3A4 activity.
METHODS: Twelve healthy volunteers (6 women, 6 men) were randomly assigned to receive C aurantium , E purpurea , milk thistle, or saw palmetto for 28 days. For each subject, a 30-day washout period was interposed between each supplementation phase. Probe drug cocktails of midazolam and caffeine, followed 24 hours later by chlorzoxazone and debrisoquin (INN, debrisoquine), were administered before (baseline) and at the end of supplementation. Presupplementation and postsupplementation phenotypic trait measurements were determined for CYP3A4, CYP1A2, CYP2E1, and CYP2D6 by use of 1-hydroxymidazolam/midazolam serum ratios (1-hour sample), paraxanthine/caffeine serum ratios (6-hour sample), 6-hydroxychlorzoxazone/chlorzoxazone serum ratios (2-hour sample), and debrisoquin urinary recovery ratios (8-hour collection), respectively. The content of purported "active" phytochemicals was determined for each supplement.
RESULTS: Comparisons of presupplementation and postsupplementation phenotypic ratios suggested that these particular supplements had no significant effect on CYP1A2, CYP2D6, CYP2E1, or CYP3A4 activity. Phytochemical profiles indicated that C aurantium was devoid of the CYP3A4 inhibitor 6',7'-dihydroxybergamottin. Quantities of fatty acids, flavonolignans, and cichoric acid were consistent with label claims for saw palmetto, milk thistle, and E purpurea , respectively.
CONCLUSIONS: Botanical supplements containing C aurantium , milk thistle, or saw palmetto extracts appear to pose a minimal risk for CYP-mediated herb-drug interactions in humans. Although the effects of E purpurea on CYP activity were minor, further study into the interaction potential of this botanical is merited.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15536458     DOI: 10.1016/j.clpt.2004.07.007

Source DB:  PubMed          Journal:  Clin Pharmacol Ther        ISSN: 0009-9236            Impact factor:   6.875


  49 in total

Review 1.  Drug interactions with herbal medicines.

Authors:  Shaojun Shi; Ulrich Klotz
Journal:  Clin Pharmacokinet       Date:  2012-02-01       Impact factor: 6.447

Review 2.  [Pharmacokinetic drug interactions by herbal drugs: Critical evaluation and clinical relevance].

Authors:  Matthias Unger
Journal:  Wien Med Wochenschr       Date:  2010-12

3.  Assessing the clinical significance of botanical supplementation on human cytochrome P450 3A activity: comparison of a milk thistle and black cohosh product to rifampin and clarithromycin.

Authors:  Bill Gurley; Martha A Hubbard; D Keith Williams; John Thaden; Yudong Tong; W Brooks Gentry; Philip Breen; Danielle J Carrier; Shreekar Cheboyina
Journal:  J Clin Pharmacol       Date:  2006-02       Impact factor: 3.126

4.  Herb-drug interactions: challenges and opportunities for improved predictions.

Authors:  Scott J Brantley; Aneesh A Argikar; Yvonne S Lin; Swati Nagar; Mary F Paine
Journal:  Drug Metab Dispos       Date:  2013-12-11       Impact factor: 3.922

5.  Population pharmacokinetics of sirolimus in de novo Chinese adult renal transplant patients.

Authors:  Zheng Jiao; Xiao-jin Shi; Zhong-dong Li; Ming-kang Zhong
Journal:  Br J Clin Pharmacol       Date:  2009-07       Impact factor: 4.335

Review 6.  Potential of pharmacokinetic profiling for detecting herbal interactions with drugs.

Authors:  Veronika Butterweck; Hartmut Derendorf
Journal:  Clin Pharmacokinet       Date:  2008       Impact factor: 6.447

7.  The effects of milk thistle (Silybum marianum) on human cytochrome P450 activity.

Authors:  Marina Kawaguchi-Suzuki; Reginald F Frye; Hao-Jie Zhu; Bryan J Brinda; Kenneth D Chavin; Hilary J Bernstein; John S Markowitz
Journal:  Drug Metab Dispos       Date:  2014-07-15       Impact factor: 3.922

Review 8.  Adverse effects of plant food supplements and botanical preparations: a systematic review with critical evaluation of causality.

Authors:  Chiara Di Lorenzo; Alessandro Ceschi; Hugo Kupferschmidt; Saskia Lüde; Elizabeth De Souza Nascimento; Ariana Dos Santos; Francesca Colombo; Gianfranco Frigerio; Karin Nørby; Jenny Plumb; Paul Finglas; Patrizia Restani
Journal:  Br J Clin Pharmacol       Date:  2015-04       Impact factor: 4.335

9.  Two flavonolignans from milk thistle (Silybum marianum) inhibit CYP2C9-mediated warfarin metabolism at clinically achievable concentrations.

Authors:  Scott J Brantley; Nicholas H Oberlies; David J Kroll; Mary F Paine
Journal:  J Pharmacol Exp Ther       Date:  2009-11-24       Impact factor: 4.030

10.  No Clinically Relevant Pharmacokinetic Interactions of a Red Clover Dietary Supplement with Cytochrome P450 Enzymes in Women.

Authors:  Luying Chen; Jaewoo Choi; Scott W Leonard; Suzanne Banuvar; Elena Barengolts; Marlos Viana; Shao-Nong Chen; Guido F Pauli; Judy L Bolton; Richard B van Breemen
Journal:  J Agric Food Chem       Date:  2020-11-16       Impact factor: 5.279

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.